Via Bandiera, 11 - 90133 Palermo, ItalyTel. +39 091 6041111 - Fax +39 091 6041122info@fondazionerimed.comwww.fondazionerimed.com

THE ITALIAN NON PROFIT TRANSLATIONAL MEDICINE BIOTECH FOUNDATION

Ri.MEDSTRATEGY

Ri.MEDFOUNDATION

TRANSLATE THE BIOMEDICAL

RESEARCH INTO PATIENT CARE

INNOVATIVE APPROACHES FOR

UNMET THERAPEUTIC AREAS

OPPORTUNITIES

PROMOTE ENTRAPRENEURSHIP

AND BUSINESS IN ITALY

ALLIANCES

FOUNDING PARTNERS

POSITIONING IN THE LIFE SCIENCE

SECTOR

Thanks to powerful international strategic alliances with the founding partners and IRCCS ISMETT (Istituto Mediterraneo per i Trapianti e Terapie ad Alta Specializzazione), Ri.MED is focused on translating the progress of biomedical research into patient care, with a special focus on the integration of advances from preclinical drug discovery, regenerative medicine, and tissue engineering.

Promote, support, and conduct biotech and biomedical research projects to rapidly transfer innovative results in the clinical practice.

Promote and sustain the development of the biotech sector in Sicily and the south of Italy in order to position this part of the country at the forefront in this research sector.

Focus on high priority therapeutic areas--e.g., end-stage organ, neurodegenerative, cardiovascular, and infectious diseases as well as inflammation and oncology.

Focus on strengths and innovation--tissue engineering, regenerative medicine, medical devices, small molecules, vaccine development, and drug discovery.

Company portfolio management based on target product profile, value proposition, generation of intellectual property.

Strategic alliances to build critical mass and synergistic competencies.

Support start-up companies.Attract public and private investors.Scouting and propelling innovation.FTE-based or fee-for-service scientific research.

Ri.MEDRESEARCH CENTER

Ri.MEDNETWORK

Ri.MEDPORTFOLIO

Integrated Drug Discovery LaboratoryVivarium and Transgenic in Vivo Model FacilityBiomedical Engineering Research LaboratoriesVaccine Development LaboratoriesMolecular Imaging LaboratoryNeuroscience LaboratorySpin-off Enterprise

LABORATORIES AND FACILITIES

NETWORKING

Ri.MED is developing an increasingly extended network of scientific collaborations: several agreements are already in place, sharing laboratories and resources with organizations across the globe, to promote research activity and develop technological innovation. A special focus is on issues related to scientific dissemination, sharing research outcomes, organizing meetings and workshops.

TRAINING

Ri.MED promotes PhD, postdoctoral fellowships andtraining programs within its scientific network at regional, national and international level.Training programs held by Ri.MED contribute to theenrichment of the overall potential offer of Sicily in thebiomedical and health care technology sector.

RotterdamErasmus Medical CenterUniversity of Rotterdam

NETHERLANDS

The Biomedical Research and Biotechnology Center (BRBC) will allow Sicily to take a leading position in the development of next generation therapeutics, engineered tissues and medical devices, contributing to affirm Italy’s role in the international scientific community:

25,000 sqm of laboratory facilities

600 people employed and about just as many in the allied industries the BRBC will help to develop

benefit for the public health: innovative devices, techniques and clinical products

economic benefit: commercial products and employment

The BRCB will be a center of reference for research in biotechnology, attracting the best researchers from all over the world and retaining in Italy our best scientists and physicians

A SCIENTIFIC DISTRICT IN THE HEART OF THE MEDITERRANEAN

Anti-inflammatory drugs for steroid-resistant airway diseases Partner: CNR

Development of new anti-inflammatory drugs: Lipid signaling in inflammationPartners:University of Pittsburgh, Complexa

TISSUE ENGINEERINGAND BIOMEDICAL

DEVICE DEVELOPMENT

IMMUNOONCOLOGY

INFECTIOUS DISEASES

Modulating protein-protein and protein-DNA interactions: New molecular targets to inhibit tumor progression and metastasisPartner: University of Pittsburgh

Advanced cell therapy for liver diseases: Adoptive immunotherapy Partners: IRCCS ISMETT, UPMC Italy

Development of novel vaccination strategies:

Eat to Heal - Yeast probiotic vaccination vector - express antigens of pathogens which use the mucosal surfaces

DNA vaccines comprising the Lysosome-Associated Membrane Protein 1 (LAMP) against Zika and DenguePartner: University of Pittsburgh

INTEGRATEDDRUG

DISCOVERY

NEUROSCIENCEWITH A FOCUS

ON RARE DISEASES

REGENERATIVEMEDICINE

Amiotrophyc lateral sclerosis (ALS): Unravel the pathogenic mechanism of ALS(peripheric/muscular origin, central/neurologic origin)Partner: University of Rome “La Sapienza”

Temporal lobe epilepsy (TLE): Side effects-free therapeutic potential of mitochondrial cannabinoid receptor 1 stimulation in the prevention of TLEPartners: University of Pittsburgh, University of Rome “La Sapienza”

Parkinson's Disease (PD) and protein misfolding diseases: Identification of new neuroprotective strategiesPartner: University of Pittsburgh

Type I diabetes: Isolation and transplant of human pancreatic islet for type I diabetes patientPartners: Diabetes Research Insitute (Miami), IRCCS ISMETT

Heart regeneration and blood coagulation: Characterization of the effect of nitrite on heart regenerationupon cryo injury and the role of globins in regenerationPartner: University of Pittsburgh

Renal tissue engineering: Lymph node stromal (LNS) cell-based system with human renal progenitorsto regenerate a functional kidney graftPartner: University of Pittsburgh

Chronic skin wounds: Fetal dermal cell-based therapy for chronic skin wound managementPartner: IRCCS ISMETT

Liver Disease: Expandable organoid lines, new strategies for the development of autologous cell therapiesand for in vitro disease modelingPartner: IRCCS ISMETT

Cardiovascular tissue engineering: Development of myocardial patch and engineered tissues(pulmonary valve leaflet and vascular grafts)Partners: University of Pittsburgh, UPMC

Osteoarthritis: 3D osteochondral (OC) microphysiological systems (MPS) to generate engineered constructs that mimic native tissuePartner: University of Pittsburgh

Personalizing decision-making in Healthcare: Cardiovascular biomechanics-computational modeling for predicting ascending thoracic aortic aneurysm to de-risk clinical outcomePartner: IRCCS ISMETT

TECHNOLOGY PLATFORMSSTRUCTURAL BIOLOGY, COMPUTATIONAL BIOLOGY, DRUG DESIGN AND VIRTUAL SCREENING, BIO AND CHEMINFORMATICS

NATIVE AND ENGINEEREDTISSUE CHARACTERIZATION

FUNCTIONAL PROTEOMICSAND SECRETOMICS PLATFORM

INTEGRATED IN SILICO AND BIOPHYSICAL APPROACHES

EBNEuropean BiotechnologyNetwork Roma

University of Rome “La Sapienza”University of Rome “Roma Tre”

SienaToscana Life SciencesFoundation

Chianciano TermeUPMC Institute for HealthChianciano Terme

NapoliSecond University of Naples

ITALY

PalermoIRCCS ISMETTIBIM - CNRIBF - CNRCHABUniversity of PalermoISZSIZS

ITALY

PittsburghUniversity of Pittsburgh

USA

MiamiDiabetes Research InstituteFoundation

USA

LondonKing's College London

UKAntwerpUniversity of Antwerp

BELGIUMZurichUniversity of Zurich

SWITZERLAND